GIP and obesity due to melanocortin 4 receptor deficiency: Retatrutide: A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide has demonstrated safety in phase II trials involving patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).